p53 and RAS gene mutations in multiple myeloma

We analysed genomic DNA from 30 patients with multiple myeloma (MM), searching for alterations in the p53 and RAS genes by a combination of polymerase chain reaction and single-strand conformation polymorphism techniques. Mutations in the p53 gene were observed in 20% (6 out of 30) of the patients,...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 7; no. 12; p. 2539
Main Authors Portier, M, Molès, J P, Mazars, G R, Jeanteur, P, Bataille, R, Klein, B, Theillet, C
Format Journal Article
LanguageEnglish
Published England 01.12.1992
Subjects
Amino Acid Sequence
Base Sequence
Codon - genetics
Exons
Genes, p53
Genes, ras
Humans
Molecular Sequence Data
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Mutation
Neoplasm Staging
Oligodeoxyribonucleotides
Oligonucleotides, Antisense
Polymerase Chain Reaction - methods
Polymorphism, Genetic
Tumor Suppressor Protein p53 - genetics
Online AccessGet more information

Cover

More Information
Summary:We analysed genomic DNA from 30 patients with multiple myeloma (MM), searching for alterations in the p53 and RAS genes by a combination of polymerase chain reaction and single-strand conformation polymorphism techniques. Mutations in the p53 gene were observed in 20% (6 out of 30) of the patients, and were located in conserved sequence blocks within exons 5 and 7. These were single-nucleotide substitutions and consisted predominantly (4/6) of G:C to A:T transitions. Of the six patients with a mutated p53 gene, four were in the terminal phase of the disease. RAS gene mutations were found more frequently since they occurred in 47% (14 out of 30) of the patients. Mutations consisted of single-nucleotide substitutions, located in codons 12, 13 and 61 of either K- or N-RAS, to the exclusion of H-RAS. Moreover, one patient bore two simultaneous mutations, affecting simultaneously the K- and the N-RAS genes. RAS gene mutations were more frequently observed in patients with fulminating disease (10/15, 67%) than in patients with less aggressive forms of the disease (4/15, 26%). We also analysed genomic DNAs from 10 human myeloma cell lines, of which two bore mutations affecting codon 12 of the K-RAS gene, and one codon 12 of the N-RAS gene. The first two cell lines were obtained from freshly explanted tumor cells in which we observed identical mutations. Results presented here show that activating mutations in the RAS genes are, in MM, more frequent than those affecting the p53 gene and suggest that both events are related to terminal phases of the disease.
ISSN:0950-9232